Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis

  • STATUS
    Recruiting
  • participants needed
    47
  • sponsor
    Hospices Civils de Lyon
Updated on 8 November 2020
Investigator
Léa SABAN-ROCHE
Primary Contact
Service Oncologie M dicale, INSTITUT DE CANCEROLOGIE DE LA LOIRE (ICL) (0.5 mi away) Contact
+2 other location

Summary

Peritoneal carcinosis (PC) corresponds to a locoregional extension into the peritoneum of rare primary peritoneal cancers, or more frequently distant extension of digestive cancers (colorectal or gastric) or gynecological (ovarian, fallopian tube, or endometrial). PC can be considered as a distinct oncological entity as its genesis, natural history, and response to systematic treatments differ to those of other metastases. The development of PC, observed in 25-35% of colorectal cancers, is generally considered as a unfavorable event in the course of the disease. The prognosis is defined by the possibility of complete resection, possibly after neoadjuvant treatment. The benefit provided by the combination of cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) with respect to systemic chemotherapy in patients with PC of colorectal origin has been demonstrated based on overall survival in several randomized trials, among which one evaluated oxaliplatin. The evaluation of the clinical benefit-risk related to the repeated administration of non-hyperthermic intraperitoneal chemotherapy, as has been validated in ovarian cancer, in patients with PC of colorectal origin is already being investigated by several international teams.

The FOLFOXIRI + bevacizumab every 2 weeks is a modern therapeutic option in patients with this disease. The intraperitoneal rather than intravenous (IV) administration of oxaliplatin, in this combination, could increase the response of peritoneal lesions known to be relatively insensitive to IV chemotherapy.

Details
Treatment intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Clinical Study IdentifierNCT02866903
SponsorHospices Civils de Lyon
Last Modified on8 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have Peritoneal Carcinosis?
years old and 75 years old
ECOG Performance Status (PS) 0-2
Peritoneal carcinosis with locoregional extension or metastases of colorectal origin and uncertain resectability
PCI > 20 and / or infiltration of the hepatic pedicle and / or necessary digestive tract resections
Systemic chemotherapy indication, compatible with the FOLFIRI + bevacizumab combination
Satisfactory haematological evaluation: PNN rate greater than 1500 / mm3, platelet count greater than 100 G / l
Satisfactory renal and hepatic function : serum creatinine 1.5 times the normal lower values or creatinine clearance 50 ml / min, bilirubin 1.25 times lower normal values, AST / ALT 1.5 times the lower normal values (5 times the lower normal values for patients with liver metastases)
No unstable conditions: myocardial infarction within 6 months prior to the start of the study, congestive heart failure, unstable angina, active cardiomyopathy, unstable rhythm disorder, uncontrolled hypertension, uncontrolled psychiatric disorders, severe infection, peptic ulcer or any condition that could be aggravated by treatment or limit compliance (investigator assessment)
No limitation in the number of previous treatments
Patients may have received conventional cytotoxic chemotherapy , hormonal or immunological targeted biological agents. They should have recovered from previous grade 2 toxicities
Written informed consent
Known RAS status

Exclusion Criteria

Extraperitoneal metastases for which the site or number preclude potentially curative surgery at any moment during the course of the disease
Sign of bowel obstruction or lesions whose topography indicates a risk of intestinal perforation or inflammatory bowel disease
ECOG PS 3-4
Contraindication to the placement of a intraperitoneal central line
Contraindication specifically related to intraperitoneal administration of oxaliplatin
known history of hypersensitivity to oxaliplatin or to the excipients
peripheral sensory neuropathy grade 2
Pregnant or lactating women
Unable to give consent
Patient under legal protection measures
Refusal to participate in the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet